Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Holdings Increased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 7.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 99,060 shares of the medical equipment provider's stock after acquiring an additional 7,043 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned 0.14% of Lantheus worth $8,862,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LNTH. State of New Jersey Common Pension Fund D grew its stake in Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after buying an additional 115 shares during the last quarter. Bleakley Financial Group LLC grew its position in shares of Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after acquiring an additional 129 shares during the last quarter. Avantax Advisory Services Inc. grew its position in shares of Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after acquiring an additional 132 shares during the last quarter. Foundry Partners LLC raised its position in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 133 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

Shares of LNTH stock traded down $3.06 during trading hours on Friday, reaching $100.58. The company had a trading volume of 257,743 shares, compared to its average volume of 950,805. The company has a market capitalization of $6.89 billion, a P/E ratio of 16.73 and a beta of 0.20. Lantheus Holdings, Inc. has a twelve month low of $63.76 and a twelve month high of $126.89. The stock's fifty day simple moving average is $97.01 and its 200 day simple moving average is $95.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. Insiders own 2.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LNTH. JMP Securities reiterated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial lifted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.